Thirty-nine subjects with CF who also had the G551D-CFTR mutation were randomized to receive ivacaftor (KalydecoTM; also known as VX-770) in four doses or placebo twice daily for at least 14 days. The gene discussed is CFTR; the disease is cystic fibrosis.